# Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

> **NCT04608630** · PHASE2 · RECRUITING · sponsor: **Australian and New Zealand Intensive Care Research Centre** · enrollment: 450 (estimated)

## Conditions studied

- Critical Illness
- Osteoporosis

## Interventions

- **DRUG:** Denosumab 60 MG/ML
- **DRUG:** Zoledronic Acid 5Mg/Bag 100Ml Inj
- **DRUG:** Sodium Chloride 0.9% or 5% Dextrose Intravenous
- **DRUG:** Sodium Chloride 0.9% Injection

## Key facts

- **NCT ID:** NCT04608630
- **Lead sponsor:** Australian and New Zealand Intensive Care Research Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-15
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608630, "Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04608630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*